Humanized anti-CCR7 receptor antibodies
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides novel humanized anti-human CCR7 antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies.
-
Citations
16 Claims
-
1-15. -15. (canceled)
-
16. A humanized anti-CCR7 antibody comprising the hypervariable regions HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2 and HVR-L3, wherein:
-
HVR-H1 comprises SEQ ID NO;
6;HVR-H2 H1 comprises SEQ ID NO;
13;HVR-H3 H1 comprises SEQ ID NO;
19;HVR-L1 H1 comprises SEQ ID NO;
27;HVR-L2 H1 comprises SEQ ID NO;
31; andHVR-L3 H1 comprises SEQ ID NO;
36,and wherein antibody has at least one of; a) a minimal affinity for a synthetic antigen with the amino acid sequence of SEQ ID NO;
76, defined by a Kd that is not more than a factor 10 higher than the Kd of a mouse anti-CCR7 antibody of which the amino acid sequence of the heavy chain variable domain is SEQ ID NO;
1 and of which the amino acid sequence of the light chain variable domain is SEQ ID NO;
2; and
,b) an IC50 of no more than 100 nM for inhibiting at least one of CCR7-dependent intracellular signalling and CCR7 receptor internalization, by at least one CCR7-ligand selected from CCL19 and CCL21.
-
Specification